Rock Springs Capital AUTL Position
Exited7-Fund ConvergenceRock Springs Capital exited their position in Autolus Therapeutics plc (AUTL) in Q1 2025, after holding the stock for 5 quarters.
The position was first reported in Q1 2024 and has been tracked across 5 quarterly 13F filings.
AUTL is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Obecabtagene autoleucel in 1049 days (Feb 28, 2029), making the timing of Rock Springs's position particularly relevant.
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Full company profile →Short Interest
8.5%
8.6 days to cover
Rock Springs Capital AUTL Position History
Frequently Asked Questions
Does Rock Springs Capital own AUTL?
No. Rock Springs Capital exited their position in Autolus Therapeutics plc (AUTL) in Q1 2025. They previously held the stock for 5 quarters.
How many hedge funds own AUTL?
7 specialist biotech hedge funds currently hold AUTL, including Deep Track Capital, Avoro Capital Advisors, Cormorant Asset Management and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy AUTL?
Rock Springs Capital's position in AUTL was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's AUTL position increasing or decreasing?
Rock Springs Capital completely exited their AUTL position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
AUTLCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →